厚生労働省医政局経済課 委託事業

後発医薬品使用促進ロードマップ検証検討事業

報告書

平成３０年３月

..................................................................................................................................... 1

.................................................................................................................................. 3 .................................................................................................................................. 3

.............................................................................................................................. 4 .............................................................................................................................. 5

........................................................................................................................... 7 ....................................................................................................................... 7 ....................................................................................................................... 9

............................................................................................................ 9 ................................................................................ 34

....................................................................................... 76 ................................................................................ 86 .............................................................................. 105

....................................................................................................................... 115 23 ............................................................................................... 117

..................................................................................................... 117 ..................................................................................................... 118

.......................................................... 118 ...................................................... 133

.......................... 138 ........................................................................ 151

................................................................................................. 163 ................................................................................................. 164

........................................................................ 164 ............................................................................ 174

.............................................................. 178 ..................................................................................................... 182

................................................................................................................... 182 ................................................................................................................... 183

................................................................................................. 183 ........................................................................................................ 201

.......................................................................................... 211 ........................................................................ 250

.......................................................................................................................... 307 ................................................................................................................... 309 ................................................................................................................... 310

....................................................................................................................... 310 ....................................................................................................................... 322

................................................................................................................... 332 ........................................................................................................ 345

...................... 359 ....................................................................................................................... 361

........................................................................................................ 361 ...................................................... 365

.......................................................................................... 371 ........................................................................................................ 371

.............................................................................................. 373 ...................................................... 374

............................................................................................................ 377 .............................................................................................. 377

...................................................... 379 .............................................................................................. 381

........................................................................................................ 381 .............................................................................................. 386

...................................................... 389 ................................................................................................. 391 ................................................................................................. 392

........................................................................................................ 392

1

1

2

2

3

25 4

26 4

196

105

23 47 23

3,500 2,500

3

4

17

31

29 11 29

230 2 16UFJ

23

330 3 16UFJ

2 3 42 5 5 6

MR Medical Representative

MRMR

MS Marketing Specialist

MS MS

4

5

2 100

5

6

6

7

196 29 10 1

29 12 15 30 1 25

28 29

28

25 26 27

3 UFJ 26 27

28 3 27

28 29 3 UFJ

28 29 3 28

29 3 2

25 26 27

7

8

105 29 10 1

29 12 15 30 1 24

28 29

28

29 3 28 29 3

1

8

9

� 5,000 1 25.5

1 5 10

4 1

� 1 21.0 100 24.0

9

10

10

11

� 85.9

14.1

� 74.0 26.0

11

12

� 100 500 26.1

500 22.8

� 500 55.0

3 3

12

13

3 29 3

13

14

MR

� 1 671.1 MR

170.1 MR MR 165.4

� 1 MR 25 212.3 26

204.4 27 188.5 28 170.1

� 1 1,713.6 MR

466.0 MR MR 461.8

MR MR

14

15

MR MR

15

16

� 9

84 10 19 30

� 100 26 27 9

4 100 1

� 4

38 10 19 20 30

18

16

17

17

18

�

79.7 27 1.9

256

� MF

35.0 27 MF

45.0 27

3.8

� 40.0

27 1.9

5.0 27

� 33.5 27 1.0

125

� MF

38.6 MF

50.3

� 46.6

13.1

18

19

19

20

�

B A 50 8

�

53.2 27 3.8

%

20

21

� 90

� 27 90

90

21

22

�

93.5 172 6.5 12

� 95.0 95 5.0 5

22

23

� 22.3

41 77.7 143

� 9.0 9 91.0 91

27

23

24

� 0

21.7 0 20 29 21.7

� 20 29

27.0 40 49 24.0 0 20.0

24

25

25

26

� 0

26.6 27 5.6 0 1

16.8

� 0

46.0 1 22.0

26

27

� 156

145 92.9 54 34.6

�

1,186 185

� 167 147

88.0 146 87.4

� 2,623

3,864

� 96

93 96.9 34 35.4

�

528 136

� 96 73

76.0 80 83.3

� 491

622

27

28

7 3 2 22

3 2 22

15 14 13 6 65 4 4 4 3

3 3 3 3 33 2 2 2 2

28

29

8 5 4 43 2 2

4 3 22

16 15 8 75 4 4 2 2

29

30 30

31 31

32

�

1.26

5.70

�

1.48

5.86

32

33

33

34

1

�

49.5 92 26.9

50

� 54.5 55

22.8 23

25

25 26 27 3 28 29 11

34

35

1

27 28 3 28 29 11

35

36

27 28 3 28 29 11

36

37

2

� 92.6 125

27 3

� 90.9 70

2525 26 27 3 28 29 11

37

38

27 28 3 28 29 11

27 28 3 28 29 11

38

39

3

�

50.0 5

� 27

25

10

25 26 27 3 28 29 11

1

39

40

4

�

23 692

� 27

260

� 12

164

25 26 12 1 26 27 11 1 2728 11 1 28 29 11 1

40

41

5

�

76.3 103

� 63.6 49

2525 26 27 3 28

29 11

41

42

27 28 3 28 29 11

27 28 3 28 29 11

42

43

1

�

81.2 151 18.3

34

� 27 5

�

56.4 57 41.6 42

25

25 26 11 26 27 11 2728 11 28 29 11

43

44

27 28 11 28 29 11

27 28 11 28 29 11

44

45

2

�

28 11 82.8 125 28 12

8.6 13

3

�

� 1

�

�

�

�

�

�

�

45

46

�

�

� 1

�

�

� 30

�

4

�

20.6 7

73.5 25

30 3 2 30 6 2

30 7 1 30 8 1 30 12 1

46

47

5

�

83.9 156 14.0 26

� 27 5

25 26 12 26 27 11 2728 11 28 29 11

27 28 11 28 29 11

47

48

27 28 11 28 29 11

6

�

�

� 1

�

�

�

�

�

�

�

�

48

49

7

�

95.2 177 3.2 6

� 93.1 94 5.0 5

25 26 12 26 27 11 2728 11 28 29 11

49

50

27 28 11 28 29 11

27 28 11 28 29 11

50

51

8

�

�

�

�

�

�

�

�

�

�

� 1

51

52

1

�

79.3 146 19.0 35

� 74.0 74

22.0 22

2.0 2

2 3 4 2 5 56

2 3 4 2 5 56

52

53

53

54

2

� 5.5 10

93.9 170

� 5.2 5 94.8 91

54

55

� 28 21 5

55

56

3

�

95.2 76.2

71.4

52.4

�

60.0

40.0

20.0

56

57

28 5

57

58

4）薬価収載後 5 年以内の後発医薬品のうち供給停止した品目数

薬価収載後 5 年以内の後発医薬品のうち供給停止した品目数は 12 品目であり、このうち、供

給停止 3 か月前までにすべての納入先保険医療機関等に直接お知らせできたのは 12 品目（全

品目）、保険医療機関等に代替品等の情報を提供したのは 12 品目（全品目）であった。

薬価収載後 5 年以内の後発医薬品のうち供給停止した品目名とその理由は以下のとおりであ

った。

図表 1- 75 薬価収載後 5年以内の後発医薬品のうち供給停止した品目数

（各年度中、複数規格がある製品の一部規格で発生した供給停止等を含む）【後発医薬品メーカー】

（単位：品目）

平成 28 年度

（n=182)

平成 27 年度

（n=178)

平成 26 年度

（n=175)

薬価収載後 5 年以内の後発医薬品のうち供給停止した

品目数（合計値） 12 2 2

うち、供給停止 3 か月前までにすべての納入先

保険医療機関等に直接お知らせできた品目数

（合計値）

12 - -

うち、保険医療機関等に代替品等の情報を提供

した品目数（合計値） 12 - -

図表 1- 76 薬価収載後 5年以内の後発医薬品のうち供給停止した品目名と

その理由（平成 28 年度）【後発医薬品メーカー】

品目名

自社の売

上高に占

めるシェア

供給停止した理由

ロサルタンカリウム錠25mg「本草」 0.01% 他社製品が多数あったため

ロサルタンカリウム錠50mg「本草」 0.35%

ロサルタンカリウム錠100mg「本草」 0.00%

ドセタキセル点滴静注液20mg/1mL「ファイザー」 0.00% 業務提携先の事業統合に伴う重複品目整

理のため ドセタキセル点滴静注液80mg/4mL「ファイザー」 0.00%

オキサリプラチン点滴静注液50mg/10mL「ファイザー」 0.09%

オキサリプラチン点滴静注液100mg/20mL「ファイザー」 0.31%

オキサリプラチン点滴静注液200mg/40mL「ファイザー」 0.03%

エピルビシン塩酸塩注射液50mg/25mL「ホスピーラ」 0.00% 会社の合併に伴う重複品目整理のため

エピルビシン塩酸塩注射液10mg/5mL「ホスピーラ」 0.00%

ゲムシタビン点滴静注用200mg「ファイザー」 0.00%

ゲムシタビン点滴静注用1g「ファイザー」 0.00%

58

59

5

� 28 207 3

185

� 5 13

� 5

59

60

1

� 3.5 3.0

� 25 26 27

60

61

2 80%

� 80

19.9 37

11.3 21

4.3 8 61.8 115

61

62

�

�

� 2

�

�

�

� OS

�

�

�

62

63

3 32 9

� 78.5 146

� 32 9

41.8 61 34.9 51

22.6 33

�

95.1 8.2

26 27 33 3

26 27 11 27 28 11 2829 11

63

64

�

64.7

26 27

1 26 27 226 28

33

64

65

�

21.6 8 37.8 14 37.8 14

4

�

75.0

72.3

�

85.1

84.2

65

66

2

66

67

67

68

68

69

69

70

5

� 3,991 40.7

� 27 2.8

70

71

6

�

10,109 82.2

� 27 15.0

26 27 11 27 28 11 2829 11

26 27 11 27 28 11 2829 11

26 27 11 27 28 11 2829 11

71

72

�

5,919 47.9

� 27 23.3

26 27 11 27 28 11 2829 11

26 27 11 27 28 11 2829 11

26 27 11 27 28 11 2829 11

72

73

7

� 28 3,793

8,829,768,552

73

74

�

�

� MF

�

�

�

�

�

�

� GMP

� FDA PMDA GMP

�

�

�

�

�

�

�

74

75

�

�

�

�

�

�

� 80

�

�

�

�

75

76

1

� 2.7 5

2

�

1 1

76

77

�

3.0

3

� 5

0

77

78

1

�

65.2 120

78

79

2

�

3.3 4

79

80

3

� 4

6 5

1

25

4

�

�

�

�

� AG GMP

�

�

� GVP

GVP

�

�

�

80

81

1

�

70.1 129

81

82

2

�

2,489 49.3

�

670 82.4

� 27

82

83

83

84

�

�

�

�

�

� 1 2 1

�

�

�

�

�

� 29

�

�

�

�

�

�

84

85

�

� ICH

� PIC/S

�

�

�

MF � MF

�

� MF

�

�

85

86

1

�

30.4 56

28.3 52 40.8 75

� 27

86

87

�

65.4

46.2 36.5

87

88

2

�

�

� MR

� MR

�

�

�

�

3

�

19.9 37

78.5 146

88

89

�

�

�

�

�

� MR

�

4

�

25.3 47 72.0 134

� 27 3.0 5

� 51.1

46.8

89

90

90

91 91

92

�

�

�

�

�

�

�

�

�

�

�

�

92

93

1 100

� 100

85.3 157

93

94

2

�

2 30.4 56 3 4

42.4 78

� 27 2 5.1

9

Fax 1 3 MR

94

95

95

96

3

� 29 1 3 3 618

1

608

4

�

54.9 101

� 27 6.3 12

96

97

97

98

5

� 28 34.7 35

6

�

29 10 30 3 30 4 30 9 25.0 3

98

99

7

�

77.9

� MR

MR

DSU

99

100

100

101

MS

1 MS

� MS

42.4 78 15.2 28

24.5 45 16.3 30

� 27

25

MRMS

101

102

102

103

2 MS

� MS

� GVP

� MR MS

� MR MS

� MR MS

� MS

� MS

�

� MS

�

� MR MS

� MS

�

�

�

�

�

� MR

103

104

� 24

�

� MR MS

�

�

�

104

105

1

�

20.1 37 78.3 144

105

106

26 20,000 1

2

�

�

�

�

�

�

�

�

�

106

107

�

�

�

�

1

� 70.1 129

28.8 53

25 188

67 121

107

108

108

109

�

52.7 51.2

50.4

� 27

7.7

109

110

� 37.2 48

45.0 58 8

�

�

�

� MR

�

�

110

111

1

� 661

44.7

� 27

� 652 44.1

�

44.4 41.1

34.4

111

112

112

113

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

� CM

�

113

114

�

� 1

� MR MR

�

114

115

� 32 9 80

�

�

�

� 80

�

�

�

�

� 80

�

5 6

7

�

�

�

115

116

�

�

�

� G1

�

�

� BCP

116

117

23

47

29 12 15 30 1 23

47 47 100.0%

117

118

� 28 83.0 39

� 8

118

119

1

2 0

3

27

4 28

27 28

119

120

1

2 0

3

27

120

121

� 28 8

5 2

1

30

30 3

12

121

122

1

1 28

23

122

123

2

� 3.4 1.4

� 12.6

12

12

3 28 23 52 2 1 1 1

1 57

123

124

124

125

3

� 64.1 25

25 26 27

1

2

125

126

4

� 15.4 6

126

127

5

� 35.9 14

6

127

128

7

� 79.5

31 27 10

8

�

� 157 970

�

�

�

�

�

�

�

�

188 114 40

�

128

129

�

�

12

9

� 46.2 18

129

130

10

� 83.3 15

27.8 5

12

28

11

� 41.0 16

27 11

1

2 26

130

131

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

12

131

132

�

�

�

�

�

�

�

�

�

�

�

�

132

133

� 20.5 8

2.6 1 76.9

30

1

2 23 27 1 26 4 282 28

3 30 1 28

133

134

�

�

�

�

� 1

� 80

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

� A H23 H24 B H25 H26

134

135

�

� 75.0 6

12.5 1 12.5 1

1

2

135

136

�

�

�

�

�

�

�

�

�

136

137

�

�

�

�

�

�

�

137

138

�

25.5 12

28

�

8.5 4 29

12.8 6 78.7 37

28

138

139

� 42.6 20

27 2

PDCA

139

140

1

� 34.0

16 27

2

1

2

140

141

3

� 53.2 25

27 10

4

1

2

141

142

5

�

55.3 26

28

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

142

143

�

�

�

�

� 740 433

�

�

�

�

�

�

�

�

�

�

� 28

�

�

�

�

�

�

�

�

�

143

144

6

�

17.0 8 27

3

�

�

�

�

�

�

�

�

144

145

� 28

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

145

146

7

�

53.2

� 25.5

12.8

146

147

8

�

14.9 7 27 2

�

�

�

�

�

�

147

148

�

�

� DPC

�

�

�

�

�

� 28

�

�

�

� H29

�

�

�

�

�

�

�

�

�

148

149

9

� 57.4 27

27

27

149

150

10

�

10.6 5

12 263 28

50mg 3mgL250 250

10 30mg 90mg

5

150

151

�

�

�

�

�

�

�

�

�

� H27.11

�

�

�

�

� 30

�

�

�

151

152

�

�

�

�

�

�

�

�

�

�

� 29 5 71.7 69.0

32 9 80

�

�

7 73.2

29 4 7 28 71.6 1.6

�

� 2018 7 72.8

2020 32 9 80

�

�

152

153

� 24 29 2 72

10

�

� 29 7

�

� 80

�

�

� MEDIAS

�

29 5

68.2 69.0

�

�

�

�

�

153

154

�

�

�

�

� 63.6 45 29 5

�

�

�

�

�

� 29 32 9 80

154

155

�

14.9 7

28

28

28

155

156

28

28

156

157

�

17.0 8

� 80

44

� A

A

� B

29 9

�

� 23 22

23 8

�

�

�

�

157

158

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

GE

�

� MR

80

�

�

158

159

�

GE

32 9 80

�

�

�

�

�

�

�

�

�

�

�

�

159

160

� PR

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

160

161

�

�

�

�

�

�

�

80

�

�

�

�

�

�

�

�

161

162

�

�

�

162

163

� 23

� 23

�

� 30 1 23 2

� 29 12 15 30 3 2

23 23 100.0%

163

164

�

100.0 23 30.4 7 17.4 4

164

165

1

� 100.0 23

165

166

2

� 25 39.1 9

26 34.8 8

3

� 95.7 22

4.3 1

166

167

4

� 65.2 15

47.8 11

5

� 29 4 29 12 9

167

168

6

�

168

169

7

�

�

�

�

�

� 3 15

�

�

�

� 25 27 28

�

�

169

170

1

�

73.9 17 69.6

16 52.2 12

� 1

� 4

�

� 28 28 2 6,900

�

�

28

�

� 10

170

171

� A

� 29 8 9 30 2 3

29 8 4,200 29 9 1,800

�

�

�

�

� 28 B 29

�

� 2 1

�

�

�

�

29

�

�

�

� 2 1

�

�

� 6

�

171

172

�

�

�

� 29 30,000

�

�

�

�

� 1

�

�

� 50

� C C

�

�

25

�

� 1

�

172

173

2

�

� 2 1

�

5

� 5

1

30 2 9

�

25

60,000

60,000

Q&A 11

� 13

� 18

� 2212

173

174

� 8.7 2 91.3 21

2 1

�

174

175

1

� 4.8 1

95.2 20

175

176

2

� 81.0 17 14.3

3

176

177

3

�

�

�

�

�

�

�

�

�

177

178

� 80

�

�

� PR

�

�

�

�

� PR

�

�

�

�

�

� 3

HP

� HP

178

179

�

�

� PR

� PR

�

�

�

� PR

�

�

�

�

�

�

�

�

�

179

180

�

�

�

�

� PR CM

�

�

�

�

�

�

� 30 PR

�

�

�

�

�

180

181

�

�

�

80

�

�

�

�

�

�

�

�

�

�

�

�

�

�

181

182

28

3

1,500

2,000

2,500

29 12 18 30 1 31

1,500 491 32.7%

2,000 516 25.8%

2,500 1,234 49.4%

182

183

1

2

183

184

3

4 DPC

184

185

5

185

186

6

186

187

7

1 42 28 271 2 2

3

187

188

8

3

3

9

188

189

10

1 1 2

189

190

190

191

1

2

191

192

192

193

3

193

194

4

1 42 28 271 2 2

3

5

194

195

6

1 1 2

195

196

196

197

7

2

197

198

8

198

199

1

�

34.6 36.2

199

200

2

�

19.6 40.3

7

200

201

201

202

202

203

3 2

203

204

204

205

205

206

206

207

207

208

3

3

208

209

1

209

210

29 3 1

29 3 1

210

211

�

89.0 83.7

�

24.6 24.4

�

58.8 45.0

� 35.8

30.8

�

80.6 78.4

�

�

29.0 22.1

211

212

5 AG 54 2

212

213

213

214

AG 14 4

4

214

215

215

216

216

217

217

218

� 89.8

9.8

�

58.9 7.5 3 2

218

219

�

MR 84.1 MS 67.8

� PMDA 26.1 28

41.5 4

� MR

32.2 MS 23.2

3 8.2

� MS

54.0 MR 49.3

� 6.2 PMDA

3.3

� MS

34.4 MR 28.8

�

MS 81.0 MR

72.6 27

� 32.5 3

� MS

38.5 MR 26.4

3 13.0

219

220

7 5 SAFE DI

5

220

221

221

222

2 2

2

222

223

223

224

224

225

225

226

1

� 28 221.5

24.3

� 26.9 21.3 22.0

� 1.3 1.0

226

227

2

� 28 45.0

28.7

� 31.4 25.5 18.0

227

228

3

� 28 342.0

32.0 27

3.5

� 34.0 25.5 7.5

� 0.3 0.0

228

229

229

230

1

� 28 41.1

10.9 27.7

� 27 9.0

3.6 4.2

230

231

2

� 28

388

31 641 1

2.2 2.4 2.1

� 89

22.9 5 16.1 177 27.6

267 68.8 24

77.4 440 68.6

� 29 7.5

11 35.5 90 14.0 27

� 3

75 19.3 2 6.5 144 22.5

27

�

247 63.7 17 54.8 373 58.2

27

231

232

3

� 28

�

232

233

4

�

�

5

4 3 2

233

234

11 2

234

235

1

� 28 17.7

2.4 20.8

� 27 1.6

0.4 1.5

2 3 42 5 5 6

235

236

2

� 28

176

22 515 1

2.6 7.3 2.5

� 17 9.7 0

0.0 68 13.2

45 25.6 3 13.6 228 44.3

� 27 4.7

236

237

3

�

27

� 1.1 27

8.9 27 2.1

237

238

4

� 28

27

0.5

6.1

238

239

5

�

239

240

2 2

2

240

241

� 13.4 0.9

4.5

241

242

12

11

10

8

7

7

2

2

2 1

242

243

12

7

4

4

3

3

A B

243

244

�

1

� 2 3

6 27

244

245

�

62.5 56.4

54.6 5

� 43.1

32.2

� 83.0 8

9 8

5

245

246

55

246

247

�

51.3 35.1 43.6

247

248

� 14.7 13.3

27.4

� 27 2.0

2.1

248

249

� 66.4

36.5 79.2

249

250

� 87.0

82.5

65.0

�

42.1 22.3

�

51.7 49.6

47.5

�

24.4 17.6

� 81.7

75.6

� 32.1

30.1

250

251

5

3 2

251

252

3 AG

3

252

253

9 AG 3

2 2

253

254

26

26

254

255

255

256

256

257

� MR

71.1 68.9

�

257

258

� 7.5

4.1 3.6

258

259

8

5

5

4

3

3

3

4

2

2

2

6

5

3

3

259

260

�

73.5 68.0

67.2 60.1

6

� 73.4 49.6

45.2

� 60.9

57.5 56.0

16 10

7 3 33

260

261

4 2

2 2

19 12

11 5 8 4

261

262

1

�

55.4 20.1 34.5

� 27

262

263

�

26.1 26.0 18.6

263

264

2

�

53.3 15.7 43.6

�

19.5 23.5 16.5

264

265

3

�

41.9 10.5 32.6

� 27 10.0 11.5

265

266

�

28.2 29.6 23.1

� 27

266

267

4

�

27.7 6.6 20.0

267

268

�

22.1 17.6

28.0

� 27 7.1 8.0

268

269

5

�

33.4

16.3 37.3

� 27 2.8 6.3

269

270

�

23.8 20.7

270

271

�

72.1 22.1 56.0

� 27

271

272

�

35.6 10.1 20.8

� 61.9 84.5 76.3

272

273

� 29 6 9 32

9 80

88.4 45.0 91.0

26 27 29 6 9

273

274

�

4

3

4

2

2

3

2

15

4

4

274

275

2

2

3

2

2

2

5

2

275

276

6

2

6

4

3

276

277

5

CM

PR

46

277

278

�

1

1

5

1 20

5

AG

1 30

5 10

278

279

279

280

80

TV

200 200

280

281

DPC

1

DPC

281

282

1 1

80

282

283

AG

AG

283

284

1

1 20 30

1 10

5

PR

CM

284

285

80

285

286

9

PR

80

1

286

287

AG

287

288

�

2 3 1

1

MR

MR

288

289

OD 56 90

OD

1 1

289

290

AG

AG

MR

MR

290

291

AG

M A

AMPC

2 3

3 4

291

292

MR

292

293

OD

PTP

PTP

CM

CM

CM

293

294

CM GE

AG

1

+

294

295

�

295

296

MR

OD

ARB

1

20 30 5 6

296

297

1 10

No.1 No.6 1

297

298

MR

MR

298

299

AG

299

300

10 7

1

A A

1

300

301

AG

MR

301

302

1

1 1

1 4 5

20 30

OD

OD

302

303

TV

60 80

1

5

303

304

80

AG

AG

AG

1

100 30 14

304

305

1 2 1 2 75

75

1

3 80

41

AG 2

305

306

AG

AG

FAX

306

307

307

308

308

309

2

2

29 12 14 30 3 26

309

310

1

28 8 2 2 610

235 20 600

100 2 50

1 2 8 3 4 2 9

10

28 25.0 29 1 27.4

25

270 6.1

310

311

2

28 27

9

7 758

85

20

7 15

4 500

1 2 3 1

1

758

758

311

312

758

758

758

3

312

313

758

3

4

28 1 6 30

30 2 12 15 20 50

1 1 283 2 368

1 2

28

27 HIV

28

313

314

HIV

28

29 1 6 29 30 2 12 18 25

55 1 1 300

2 80 300 81 470

29 2

1 28 2 3

29 1 2

6 12

6

1

30 1 6 8 2 12 2 3

3

314

315

36.4% 41.3% 45.7%55.6% 58.9% 59.9% 61.6%

0102030405060708090

100

25 4 26 5 27 4 28 3 28 8 29 2 29 8

[%]

315

316

1

70%9

65.069.91460.0

64.9%20

55.059.9%

15

50.054.9%3

40%1

316

317

128 1,600

227 4

462

3

26

2 1

28

29

43,726

116,589

208,706

336,627

40,548

72,708

130,335

154,897

0

30,000

60,000

90,000

120,000

150,000

180,000

050,000

100,000150,000200,000250,000300,000350,000400,000

25 26 27 28

1

[ ][ )

317

318

30

1Q&A

Q&A 28 297,500

227 4

475

3

1,537,525

316,751

1,672,576

0

300,000

600,000

900,000

1,200,000

1,500,000

1,800,000

26 27 28[ ] [ ]

318

319

1

228 6

6

329

19 2

1

CM

2

32 6

Q&A

319

320

1

28 3,500 10,000

2

29 4

2016 6

1

320

321

2

70 72.0

66.1

30 Z2

CM

380

1

321

322

1

29 100

1

1

10

5

322

323

2

MS

OD

3MS

40 7,000

AG AG

10 10

323

324

1

28 5 10 5

4

1

28 61

17 6 5

28

MS

140 100

5 AG

MR MR

324

325

AG

AG

MR

2

MS MR

PR MR MS

1 35 5

MR

MS MR

MR MR

MR

MR

3

29 9

10.6 42.2

31.8 6.5

325

326

28 5 29 9 9

0.6 0.7

70 80

MR

3

MR

MR

6

326

327

1

28 533 394 84 55

28

3

MR

MS

28 110

55 41 14

3

327

328

3

1

128 7

7

1 20

1 5

2

QR

328

329

3

G1

1

28 381 88 86

555 Ca 27

26 25 24

5 128

A B

28 42 6 5

53 9

6 6 5

329

330

MS

28 142

MR 5 6

2

MS

PTP

MR

330

331

3

1

1

50 10

331

332

1

25 26 3 6 4 25

Q&A

29 3 6

GE

GQP

332

333

2

26 7 22

GE GE

PMDA

333

334

3

28 GE

GE

4

GE

GE

GE

5

334

335

1

80

GE

26

27

28

27 10 20 PMDA

27 19 28 10 29 12

12 15 44

24 7 GE 28 1

9 1 5 3

5

335

336

28

80

2020 9

29 80

2

28 89 47 42

GE

336

337

11 16 27 14 28

25 28 10 28

GE

3

28 GE

3 28

28

28

4

WEB

337

338

30 2 18

14

GE

29

29 9 42 41

1

28

338

339

1

1

2

2

1 1

1

2 1

1

1

1

1

1

1

2 1

1

339

340

1

29

29 12

2 3

GMP

340

341

2

AG

3

PTP

50 10 40

32

341

342

1

50

24

342

343

MS

2

MS

MS 2010 29 11 1,075

MS

1 6

MS 1

MS

343

344

3

1 2

R

2 6

84

344

345

345

346

346

347

26 4

IQVIA IMS Health Quintiles Quintiles IMS IQVIA MIDAS

24 8 22

3

12

22017 2016 10 2017 9 2018 1

33

27

347

348

MIDAS

2015 27 4 MIDAS

2 EARLY ENTRY GENERIC PRODUCTS

BIO-COMPARABLE PRODUCTS”

27 2014 2013 10 2014 9

2015 2014 10 2015 9

2014

MIDAS 2015 2014 10

2015 9

Copyright © 2018 IQVIA

GENERICPRODUCTS

NON-GENERICPRODUCTS

NEVERPROTECTED

NO LONGERPROTECTED

NEVERPROTECTED

NO LONGERPROTECTEDPROTECTED

ANY OTHERCOMBINATION

NEVERPROTECTED

EARLY ENTRY GENERIC PRODUCTS

PROTECTED

BIO-COMPARABLEPRODUCTS

LAUNCHED UNDER ANY BIOSIMILAR

APROVALPATHWAY

NON-CATEGORISEDPRODUCTS

OTHERPRODUCTS

348

349

GENERIC PRODUCTS NEVER PROTECTED NO LONGER PROTECTED

GENERIC PRODUCTS IQVIA

EARLY ENTRY GENERIC PRODUCTS

PROTECTED

BIO-COMPARABLE PRODUCTS LAUNCHED UNDER ANY BIOSIMILARAPPROVAL PATHWAY

NON-GENERIC PRODUCTS NO LONGER PROTECTED

IQVIA

PROTECTED

NON GENERIC PRODUCTS PROTECTED

Copyright © 2018 IQVIA

IQVIA MIDAS

MIDAS

2013 25 2013 4

2014 3 70.9 2014 26 73.1 2015 27

76.7 2016 28 80.5

MIDAS IQVIA Standard Units SU

SU IQVIA

1SU 1 1

1 5ml 0.1ml 0.05ml

SU IQVIA

349

350

26 IQVIA

IQVIA

IQVIA

350

351

IQVIA MIDAS

GENERIC PRODUCTS

EARLY ENTRY GENERIC PRODUCTS

BIO-COMPARABLE PRODUCTSNON-GENERIC PRODUCTS

IQVIA, MIDAS, Market Segmentation, MAT Sep 2017, RX only PRESCRIPTION BOUNDSU IQVIA MIDAS data

IQVIA2016.4 2017.3 80.5

100Copyright © 2018IQVIA, MIDAS, Market Segmentation, MAT Sep 2017, RX only PRESCRIPTION BOUND

92.3%

61.9%

86.8%77.1%

58.9%68.0% 64.3%

7.7%

38.1%

13.2%22.9%

41.1%32.0% 35.7%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

351

352

GENERIC PRODUCTS

EARLY ENTRY GENERIC PRODUCTS

BIO-COMPARABLE PRODUCTSNON-GENERIC PRODUCTS

IQVIA, MIDAS, Market Segmentation, MAT Sep 2016, RX only PRESCRIPTION BOUNDLCD IQVIA MIDAS data

IQVIA2016.4 2017.3 80.5

100Copyright © 2018IQVIA, MIDAS, Market Segmentation, MAT Sep 2017, RX only PRESCRIPTION BOUND

52.0%

32.4%

53.5% 54.1%40.6%

49.2% 43.9%

48.0%

67.6%

46.5% 45.9%59.4%

50.8% 56.1%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

352

353 353

354

354

355

GEN

ERIC

PR

OD

UC

TSEA

RLY

EN

TRY

GEN

ERIC

PR

OD

UC

TS

BIO

-CO

MPA

RA

BLE

PR

OD

UC

TSN

ON

-GEN

ERIC

PR

OD

UC

TS 2013

.10

2014

.920

14IQ

VIA

, MID

AS,

Mar

ket S

egm

enta

tion,

MAT

Sep

201

4, R

X o

nly

PRES

CR

IPTI

ON

BO

UN

DSU

IQV

IA M

IDA

S da

taIQ

VIA

2013

.420

14.3

70.9

2015

IQV

IA, M

IDA

S, M

arke

t Seg

men

tatio

n, M

AT S

ep 2

015,

RX

onl

yPR

ESC

RIP

TIO

N B

OU

ND

SUIQ

VIA

MID

AS

data

IQV

IA20

14.4

2015

.373

.120

16IQ

VIA

, MID

AS,

Mar

ket S

egm

enta

tion,

MAT

Sep

201

6, R

X o

nly

PRES

CR

IPTI

ON

BO

UN

DSU

IQV

IA M

IDA

S da

taIQ

VIA

2015

.420

16.3

76.7

2017

IQV

IA, M

IDA

S, M

arke

t Seg

men

tatio

n, M

AT S

ep 2

017,

RX

onl

yPR

ESC

RIP

TIO

N B

OU

ND

SUIQ

VIA

MID

AS

data

IQV

IA20

16.4

2017

.380

.510

0C

opyr

ight

© 2

018I

QV

IA, M

IDA

S, M

arke

t Seg

men

tatio

n, M

AT S

ep 2

017,

RX

onl

yPR

ESC

RIP

TIO

N B

OU

ND

355

356

356

357

GEN

ERIC

PR

OD

UC

TSEA

RLY

EN

TRY

GEN

ERIC

PR

OD

UC

TS

BIO

-CO

MPA

RA

BLE

PR

OD

UC

TSN

ON

-GEN

ERIC

PR

OD

UC

TS 2013

.10

2014

.920

14IQ

VIA

, MID

AS,

Mar

ket S

egm

enta

tion,

MAT

Sep

201

4, R

X o

nly

PRES

CR

IPTI

ON

BO

UN

DLC

DIQ

VIA

MID

AS

data

IQV

IA20

13.4

2014

.370

.9

2015

IQV

IA, M

IDA

S, M

arke

t Seg

men

tatio

n, M

AT S

ep 2

015,

RX

onl

yPR

ESC

RIP

TIO

N B

OU

ND

LCD

IQV

IA M

IDA

S da

taIQ

VIA

2014

.420

15.3

73.1

2016

IQV

IA, M

IDA

S, M

arke

t Seg

men

tatio

n, M

AT S

ep 2

016,

RX

onl

yPR

ESC

RIP

TIO

N B

OU

ND

LCD

IQV

IA M

IDA

S da

taIQ

VIA

2015

.420

16.3

76.7

2017

IQV

IA, M

IDA

S, M

arke

t Seg

men

tatio

n, M

AT S

ep 2

017,

RX

onl

yPR

ESC

RIP

TIO

N B

OU

ND

SUIQ

VIA

MID

AS

data

IQV

IA20

16.4

2017

.380

.520

1420

1520

161

2016

2017

120

1720

181

100

Cop

yrig

ht ©

201

8IQ

VIA

, MID

AS,

Mar

ket S

egm

enta

tion,

MAT

Sep

201

7, R

X o

nly

PRES

CR

IPTI

ON

BO

UN

D

357

358

358

359

359

360

360

361

5

28

25

18 3 10

26

28

29

25

361

362

28

28 6 16 12 8

34

29

29 6 15 12 7

13

28

28

UFJ

29

29

UFJ

28

32

27

29

24

25

362

363

25 28

28 2

28 34

28 17.7 2.4

20.8

37.9

22.4 27.6 3.8

1.1 15.8

8.9 2.1

14.3

363

364

28

5.5 5.2

364

365

95

25

26

25

27

6025

365

366

29

29 11 1

23 100.0

25

26 3

29

186 151 81.2

101 57 56.4

41 100

34

28

29 3 6

148

290

28

26

1 27

27 12 9 10 8

27 11 20

366

367

28

29 11

186 156 83.9 26 14.0

86.6 100.0

186 177

95.2 96.5

100.0

2 3 4 2 5 5

6

28 184 146 79.3

35 19.0 1

0.5

28 10 21

181 5.5

28 5 5

96 5.2

28 17.7 2.4

20.8

25.6 13.6 44.3

9.7 0.0 13.2

21 15 71.4

5 3 60.0

24.1 20.0 14.0

367

368

29 11 80

186 37 19.9 21

11.3

186 123 66.1

174 3.5 3.0 29

3

28

41.1 10.9

27.7

28

13.4 4.5

1 2.3 2.1

135 125 92.6

77 70 90.9

100.0

29 11 1

23 692

25 28

34

368

369

28 21

5

25

28.6 26 32.9 27 37.9 28 40.7

369

370

80

1

370

371

25

28

28 9 7 29 3 3

No.6 28 6 No.7 28 12

PMDA

28 WG

29 3 31

29

29 8 28 30 3 14

No.8 29 5 No.9 30 1

PMDA

28

371

372

30 2 200

28

28 890 52

29

29

28

5

28 PMDA 77

29

5

55.4 20.1 34.5

53.3 15.7 43.6

372

373

28

47 39 83.0 28 8

28 39

6 15.4

14 35.9

31 79.5

10

28

39 18 46.2 21

53.8 18

5 27.8

28 39 28

8

373

374

28

25

25

374

375

28

28 89 47 42

184 120 65.2

63 34.2

28

4 27 3

28

12 6

6

184 129

70.1 29 3

41 40 97.6

5,046 2,489

813 670 29 3

49.3 82.4

1

3.0 2

375

376

7

34.6 35.4

5

87.4 53.9 50.3 48.5 44.3

36.5

83.3 32.3 30.2 30.2 29.2

28.1

376

377

1.26 1.48

5

5.70 0.97 0.68 0.67

0.66 0.59

5.86 0.88 0.70 0.55

0.51 0.51

PMDA

25

24

28 39

8 20.5

1 2.6 30 76.9

377

378

28 47 27 57.4

27 14 51.9

13 48.1 8 29.6

8 8

80

80

23

378

379

26

25

25MR

100

124

MS MR MS

25

28

25

web

3 28

28

28

379

380

100 184

157 85.3 9 4.9

59.9 37.2 42.1

56.2 51.7

44.0

29 1 3 618

1 608 98.4

184 101 54.9

12 6.5 47 25.5

16 8.7

MS 184 78 42.4

28 15.2 30 16.3

45 24.5

MR 7

73.5 68.0

67.2 60.1

73.4

60.9 57.5 56.0

MS

380

381

MS

2

Q&A

Q&A 25

25

2529

381

382

25

28

1 726

1 JR

11/23 16 2/12 17

29

1 1,629

28

28

UFJ

29

29

UFJ

28

TV 2016

382

383

CD

29

28

29

28

29

28

29

28

28 11 3 70

80

29

2

383

384

3 3

28

28 7

29

29 8

30

28

29

28

30

384

385

GE

385

386

25

25

25

25

25

25

28

47 39 83.0 28

8

386

387

29

28

39 35 89.7

28 39

6 15.4

14 35.9

31 79.5

10

28 39

8 20.5

1 2.6 30 76.9

28

39 18 46.2 21

53.8 18

5 27.8

47 8 17.0

47 7 14.9

387

388

28 39 28

8

28

80

80

23

388

389

25

28

28 WEB

29 3 184 129 70.1

29 3

1,478 661

26 1,268 28 652

51.3 35.1 43.6

34.2 30.3 36.6

3

389

390

97.6

28

44.7

390

391

28 610

270

27 758

28 50 1

3.4

23

28 1 2

28 1,600

27 4 462

2 1

28

167

23 17

391

392

25

25

25

28

28

392

393

29

28

29

28

28

28 28

29

28 29

393

394 394

全国健康保険協会作成　地域別ジェネリックカルテ（都道府県別） 平成29年10月版

【医療機関の視点】

院外処方ジェネリック医薬品使用割合

偏差値 指標数値影響度（※13）

01 北海道 56 71.0 53 61.6 + 0.3 39 74.3 - 0.1 52 58.7 + 0.1 54 61.0 + 0.2 55 20.1 56 73.3 + 1.6 58 73.4 + 0.8 54 73.2 + 0.8 45 43.9 56 73.3 + 1.6 58 83.6 55 79.9 59 15.1 55 60.1 62 + 2.4

02 青森 61 72.8 68 69.6 + 1.6 52 78.6 + 0.0 51 58.1 + 0.0 73 71.0 + 1.6 58 17.8 57 73.5 + 1.8 40 67.3 - 0.7 62 75.7 + 2.5 43 43.0 57 73.5 + 1.8 68 87.1 58 82.2 68 11.6 49 57.6 62 + 2.4

03 岩手 67 75.5 63 66.9 + 1.2 54 79.3 + 0.0 64 68.7 + 0.4 60 64.1 + 0.6 57 18.8 68 77.4 + 5.0 74 78.8 + 2.0 65 76.8 + 3.0 55 48.1 68 77.4 + 5.0 69 87.3 57 81.2 67 12.2 70 66.4 56 + 1.8

04 宮城 60 72.4 58 64.3 + 0.8 46 76.6 - 0.0 51 58.1 + 0.0 60 64.3 + 0.7 57 18.8 59 74.3 + 2.5 56 72.8 + 0.5 59 74.9 + 2.0 47 44.8 59 74.3 + 2.5 63 85.2 57 81.2 61 14.3 55 59.9 55 + 1.8

05 秋田 52 69.5 44 57.3 - 0.5 60 81.2 + 0.1 59 64.6 + 0.2 36 51.6 - 0.8 61 16.4 52 71.8 + 0.4 61 74.5 + 1.2 46 70.2 - 0.7 56 48.4 52 71.8 + 0.4 56 83.1 61 83.6 55 16.7 57 61.0 60 + 2.2

06 山形 61 72.8 66 68.3 + 1.9 59 80.8 + 0.1 60 65.5 + 0.2 66 67.4 + 1.5 52 22.5 58 74.2 + 2.2 58 73.5 + 0.7 58 74.4 + 1.5 60 50.4 58 74.2 + 2.2 58 83.7 52 77.5 52 17.8 63 63.2 40 + 0.3

07 福島 55 70.5 61 65.9 + 1.3 49 77.4 - 0.0 54 60.1 + 0.1 64 66.6 + 1.2 50 23.4 52 71.9 + 0.5 48 69.9 - 0.2 53 72.6 + 0.6 43 42.8 52 71.9 + 0.5 56 82.9 50 76.6 55 16.4 51 58.5 59 + 2.1

08 茨城 49 68.3 47 58.7 - 0.3 51 78.2 + 0.0 53 60.0 + 0.1 44 55.9 - 0.4 55 20.5 48 70.8 - 0.4 50 70.5 - 0.0 48 70.9 - 0.4 46 44.4 48 70.8 - 0.4 45 79.2 55 79.5 45 20.2 55 60.2 53 + 1.5

09 栃木 46 67.0 42 56.1 - 1.2 43 75.4 - 0.0 50 57.5 + 0.0 40 53.6 - 1.0 39 31.2 51 71.7 + 0.3 47 69.7 - 0.2 53 72.5 + 0.5 63 51.8 51 71.7 + 0.3 47 80.2 39 68.8 43 21.1 42 54.6 59 + 2.1

10 群馬 52 69.5 56 63.5 + 1.2 52 78.4 + 0.0 51 58.2 + 0.0 59 63.8 + 1.3 33 35.8 55 72.9 + 1.0 52 71.3 + 0.1 56 73.7 + 0.9 58 49.3 55 72.9 + 1.0 53 82.1 33 64.2 57 15.8 58 61.2 33 - 0.4

11 埼玉 53 69.7 49 59.7 - 0.1 47 76.7 - 0.0 54 60.3 + 0.1 47 57.6 - 0.2 57 19.0 52 72.0 + 0.6 53 71.7 + 0.3 52 72.2 + 0.3 53 47.4 52 72.0 + 0.6 52 81.6 57 81.0 54 17.0 57 61.0 52 + 1.4

12 千葉 53 70.0 52 61.4 + 0.2 57 80.1 + 0.0 61 66.5 + 0.4 46 56.9 - 0.3 57 18.7 52 71.9 + 0.5 51 71.0 + 0.1 52 72.3 + 0.4 45 43.9 52 71.9 + 0.5 48 80.5 57 81.3 45 20.1 57 61.1 56 + 1.8

13 東京 41 65.2 42 55.8 - 0.7 56 79.8 + 0.0 42 51.3 - 0.3 38 52.7 - 0.6 59 17.2 37 67.0 - 3.6 39 67.0 - 0.8 37 67.0 - 2.8 39 41.1 37 67.0 - 3.6 33 75.6 59 82.8 38 22.7 39 53.6 55 + 1.7

14 神奈川 50 68.6 48 59.4 - 0.1 58 80.7 + 0.0 58 63.8 + 0.2 39 53.2 - 0.5 65 13.3 46 70.0 - 1.2 53 71.7 + 0.2 44 69.3 - 1.5 50 45.9 46 70.0 - 1.2 42 78.4 65 86.7 46 20.0 56 60.6 59 + 2.1

15 新潟 54 70.1 36 52.8 - 1.3 32 71.7 - 0.1 23 35.8 - 1.6 57 62.9 + 0.3 57 19.1 57 73.8 + 2.1 45 68.9 - 0.4 62 75.8 + 2.5 62 51.1 57 73.8 + 2.1 62 85.0 57 80.9 54 17.1 48 57.2 57 + 1.9

16 富山 55 70.5 53 62.0 + 0.6 72 85.1 + 0.1 53 59.6 + 0.2 54 60.9 + 0.4 36 33.2 60 74.7 + 2.3 55 72.3 + 0.4 63 76.4 + 1.9 51 46.6 60 74.7 + 2.3 56 83.0 36 66.8 57 15.8 50 58.2 44 + 0.7

17 石川 51 69.2 52 61.5 + 0.4 46 76.4 - 0.0 51 58.3 + 0.1 53 60.6 + 0.4 39 31.1 54 72.7 + 1.0 52 71.3 + 0.2 57 74.0 + 0.9 51 46.5 54 72.7 + 1.0 47 80.1 39 68.9 59 15.2 61 62.5 50 + 1.3

18 福井 54 70.4 62 66.3 + 2.7 52 78.4 + 0.0 61 65.9 + 0.9 63 65.6 + 2.1 22 43.1 56 73.5 + 1.2 60 74.1 + 0.9 54 72.9 + 0.4 68 53.5 56 73.5 + 1.2 48 80.3 22 56.9 50 18.4 53 59.2 25 - 1.1

19 山梨 34 62.3 44 57.3 - 0.6 51 78.2 + 0.0 65 69.3 + 0.3 37 52.2 - 1.0 57 19.1 27 63.5 - 6.3 31 64.2 - 1.9 26 63.1 - 4.3 24 34.5 27 63.5 - 6.3 29 74.3 57 80.9 32 25.0 42 54.7 38 + 0.1

20 長野 56 71.0 50 60.3 + 0.0 62 81.9 + 0.1 48 55.5 - 0.1 50 59.0 + 0.0 51 22.8 59 74.2 + 2.3 59 73.7 + 0.9 58 74.6 + 1.4 50 46.1 59 74.2 + 2.3 55 82.8 51 77.2 59 14.9 55 60.2 49 + 1.2

21 岐阜 46 67.0 46 58.2 - 0.5 41 74.9 - 0.1 36 46.5 - 0.7 53 60.6 + 0.3 45 26.9 47 70.2 - 0.8 44 68.6 - 0.4 48 70.8 - 0.4 59 49.8 47 70.2 - 0.8 48 80.4 45 73.1 40 22.1 43 55.3 59 + 2.1

22 静岡 52 69.5 47 58.6 - 0.4 47 76.7 - 0.0 51 58.4 + 0.1 45 56.2 - 0.4 53 21.7 53 72.5 + 0.9 51 70.9 + 0.0 54 72.9 + 0.8 60 50.1 53 72.5 + 0.9 53 82.0 53 78.3 32 25.2 54 59.5 52 + 1.5

23 愛知 48 67.9 46 57.9 - 0.7 47 77.0 - 0.0 48 55.5 - 0.1 46 57.0 - 0.4 42 29.2 52 71.9 + 0.4 52 71.5 + 0.1 51 72.0 + 0.2 62 50.9 52 71.9 + 0.4 50 81.0 42 70.8 45 20.1 42 54.7 58 + 2.0

24 三重 48 68.0 47 58.5 - 0.5 42 75.2 - 0.0 41 50.6 - 0.4 51 59.3 + 0.1 41 29.8 52 72.1 + 0.6 51 70.8 + 0.0 53 72.6 + 0.5 57 49.1 52 72.1 + 0.6 56 83.1 41 70.2 54 16.9 49 57.6 50 + 1.3

25 滋賀 54 70.4 58 64.5 + 0.9 53 78.8 + 0.0 63 67.4 + 0.2 57 62.7 + 0.6 52 22.1 52 72.1 + 0.6 48 69.8 - 0.2 54 73.2 + 0.8 41 41.9 52 72.1 + 0.6 54 82.4 52 77.9 53 17.4 41 54.3 64 + 2.6

26 京都 39 64.6 46 58.2 - 0.7 42 75.2 - 0.1 44 52.8 - 0.2 48 57.9 - 0.3 35 34.3 40 68.1 - 2.1 40 67.1 - 1.0 42 68.7 - 1.1 32 38.3 40 68.1 - 2.1 40 77.6 35 65.7 39 22.6 43 55.3 54 + 1.6

27 大阪 41 65.2 47 58.7 - 0.5 54 79.3 + 0.0 46 53.8 - 0.2 48 58.1 - 0.2 41 29.8 40 68.0 - 2.3 42 68.0 - 0.5 40 67.9 - 1.8 44 43.4 40 68.0 - 2.3 36 76.3 41 70.2 38 23.0 38 53.1 49 + 1.2

28 兵庫 49 68.5 53 61.6 + 0.3 58 80.6 + 0.1 58 63.8 + 0.3 49 58.5 - 0.1 51 22.9 47 70.5 - 0.7 50 70.7 + 0.0 46 70.3 - 0.7 45 43.6 47 70.5 - 0.7 44 79.1 51 77.1 36 23.5 47 56.7 58 + 2.0

29 奈良 36 63.1 28 48.7 - 4.1 23 68.8 - 0.2 22 35.2 - 2.6 40 54.0 - 1.1 31 37.1 50 71.2 - 0.1 52 71.3 + 0.1 49 71.0 - 0.2 51 46.3 50 71.2 - 0.1 46 79.6 31 62.9 38 22.8 26 47.9 64 + 2.5

30 和歌山 39 64.3 45 57.6 - 1.0 42 75.2 - 0.0 50 57.5 + 0.0 46 56.7 - 0.7 29 38.3 42 68.7 - 1.6 34 65.0 - 1.2 47 70.5 - 0.4 43 42.8 42 68.7 - 1.6 47 79.9 29 61.7 51 18.0 41 54.2 61 + 2.3

31 鳥取 55 70.7 55 62.8 + 0.7 64 82.3 + 0.1 56 62.2 + 0.2 54 60.9 + 0.4 46 26.7 57 73.6 + 1.7 53 71.8 + 0.3 59 74.7 + 1.4 46 44.2 57 73.6 + 1.7 62 85.0 46 73.3 53 17.4 50 58.1 37 + 0.1

32 島根 58 71.8 61 66.2 + 1.3 65 82.8 + 0.1 54 60.8 + 0.1 61 64.8 + 1.0 53 21.8 56 73.4 + 1.6 59 73.7 + 0.7 55 73.2 + 0.9 40 41.8 56 73.4 + 1.6 63 85.2 53 78.2 66 12.3 58 61.4 31 - 0.5

33 岡山 45 66.9 47 58.6 - 0.5 51 78.2 + 0.0 46 54.0 - 0.4 50 59.1 + 0.0 32 36.1 50 71.2 - 0.1 51 70.8 + 0.0 49 71.4 - 0.1 65 52.5 50 71.2 - 0.1 49 80.6 32 63.9 55 16.7 43 55.3 31 - 0.6

34 広島 45 66.7 50 60.2 - 0.0 48 77.0 - 0.0 52 58.7 + 0.1 48 58.1 - 0.1 51 22.6 42 68.5 - 2.1 40 67.2 - 0.7 43 69.0 - 1.4 56 48.8 42 68.5 - 2.1 43 78.8 51 77.4 47 19.5 46 56.2 53 + 1.6

35 山口 54 70.1 53 61.7 + 0.3 48 77.1 - 0.0 60 65.6 + 0.4 49 58.4 - 0.1 51 23.1 54 72.6 + 1.0 47 69.7 - 0.2 56 73.8 + 1.2 52 46.7 54 72.6 + 1.0 58 83.6 51 76.9 63 13.6 55 60.1 53 + 1.5

36 徳島 21 57.4 29 49.3 - 3.9 34 72.4 - 0.1 40 49.1 - 0.9 28 47.4 - 2.6 33 35.7 22 62.0 - 6.0 21 60.6 - 2.1 25 62.6 - 3.8 33 38.7 22 62.0 - 6.0 34 75.8 33 64.3 39 22.5 20 45.5 34 - 0.2

37 香川 41 65.2 43 56.4 - 1.0 37 73.5 - 0.1 49 56.9 - 0.0 41 54.0 - 0.9 47 25.8 41 68.3 - 2.2 41 67.4 - 0.9 42 68.8 - 1.3 48 45.2 41 68.3 - 2.2 45 79.3 47 74.2 48 19.2 42 54.7 51 + 1.4

38 愛媛 40 64.8 40 55.0 - 1.9 39 74.2 - 0.1 43 51.9 - 0.5 41 54.3 - 1.2 32 35.8 48 70.5 - 0.5 53 71.8 + 0.3 44 69.5 - 0.8 44 43.3 48 70.5 - 0.5 61 84.8 32 64.2 55 16.6 50 58.1 38 + 0.2

39 高知 33 62.0 35 52.6 - 1.9 38 73.9 - 0.1 42 50.9 - 0.4 34 50.3 - 1.5 48 25.3 32 65.2 - 4.6 30 63.6 - 2.7 37 66.8 - 1.8 33 38.6 32 65.2 - 4.6 32 75.2 48 74.7 50 18.5 39 53.4 50 + 1.2

40 福岡 52 69.7 58 64.2 + 0.8 54 79.0 + 0.0 60 64.9 + 0.6 52 60.2 + 0.1 53 21.4 49 71.1 - 0.1 49 70.2 - 0.1 50 71.4 - 0.1 52 46.7 49 71.1 - 0.1 51 81.3 53 78.6 60 14.8 59 61.6 48 + 1.1

41 佐賀 58 72.0 54 62.5 + 0.3 47 76.8 - 0.0 42 51.4 - 0.2 57 62.7 + 0.3 62 15.7 57 73.6 + 2.0 49 70.1 - 0.1 60 75.3 + 2.1 63 51.6 57 73.6 + 2.0 57 83.4 62 84.3 56 16.1 57 61.0 59 + 2.1

42 長崎 55 70.9 61 65.9 + 1.3 50 77.8 - 0.0 57 63.1 + 0.3 61 64.7 + 0.9 51 22.9 53 72.4 + 0.8 57 73.2 + 0.7 51 71.9 + 0.2 37 40.2 53 72.4 + 0.8 60 84.2 51 77.1 61 14.3 58 61.5 54 + 1.6

43 熊本 54 70.2 59 65.0 + 1.4 52 78.6 + 0.0 59 64.2 + 0.5 59 63.6 + 0.9 42 29.1 53 72.4 + 0.7 50 70.5 - 0.0 54 73.1 + 0.8 62 51.1 53 72.4 + 0.7 54 82.3 42 70.9 59 15.0 59 61.6 46 + 0.9

44 大分 47 67.7 53 61.9 + 0.4 37 73.7 - 0.1 45 53.2 - 0.2 58 63.2 + 0.7 48 25.1 45 69.6 - 1.3 46 69.3 - 0.4 45 69.7 - 0.9 46 44.1 45 69.6 - 1.3 48 80.5 48 74.9 48 19.0 39 53.6 29 - 0.7

45 宮崎 59 72.2 50 60.4 + 0.0 39 74.1 - 0.1 50 57.5 + 0.0 51 59.4 + 0.0 55 20.5 61 75.1 + 3.0 58 73.3 + 0.6 62 75.7 + 2.4 49 45.5 61 75.1 + 3.0 67 86.6 55 79.5 66 12.7 53 59.2 43 + 0.6

46 鹿児島 68 75.9 67 68.8 + 2.0 51 78.2 + 0.0 64 68.8 + 0.9 65 67.0 + 1.0 51 23.3 70 78.0 + 5.2 64 75.4 + 1.1 71 79.1 + 4.1 71 55.1 70 78.0 + 5.2 63 85.3 51 76.7 68 11.7 61 62.6 47 + 0.9

47 沖縄 81 80.8 82 76.7 + 2.9 75 86.0 + 0.2 78 79.8 + 1.1 76 72.7 + 1.4 58 17.9 81 81.6 + 8.5 76 79.6 + 2.3 81 82.5 + 6.2 56 48.7 81 81.6 + 8.5 73 88.7 58 82.1 74 9.6 72 67.2 54 + 1.6

- 全体 - 68.7 - 60.2 - - 77.8 - - 57.3 - - 59.0 - - 23.7 - 71.3 - - 70.6 - - 71.6 - - 45.9 - 71.3 - - 81.0 - 76.3 - 18.4 - 58.0 - + 1.3

※1　地域別の集計は、医療機関および薬局の所在地に基づく。※2　平成29年10月診療分の医科、DPC、調剤レセプトを対象とする。DPCについてはコーディングデータを集計対象とする。※3　数量は、薬価基準告示上の規格単位毎に数えたもの。ただし、経腸成分栄養剤、特殊ミルク製剤、生薬、漢方を除く。※4　ジェネリック医薬品使用割合は、数量ベース新指標にて算出。後発品数量 ÷（後発のある先発品数量＋後発品数量）※5　後発品の有無に関する情報は、厚生労働省「各先発医薬品の後発医薬品の有無に関する情報」に基づく。※6　実質院内処方率として、医薬品処方数量に基づいて算出している。（院内処方医薬品数量）/（院内処方医薬品数量＋院外処方医薬品数量）※7　実質一般名処方率として、一般名処方加算にヒモ付くレセプト数に基づいて算出している。（一般名処方加算1または2が存在する医科レセプトに、支部、記号、番号、性別、生年月日がヒモ付く調剤レセプトの数）/（調剤レセプトの数）※8　一般名処方加算1が存在する医科レセプトに、支部、記号、番号、性別、生年月日がヒモ付く調剤レセプトのみを集計対象とする。※9　実質院外処方率として、医薬品処方数量に基づいて算出している。（院外処方医薬品数量）/（院内処方医薬品数量＋院外処方医薬品数量）※10　（調剤レセプトの加入者の都合で後発品を調剤しなかったコメントレコードのあるレセプト数）/（一般名処方加算が存在する医科レセプトに、支部、記号、番号、性別、生年月日がヒモ付く調剤レセプト数）※11　国公費の記載のあるレセプトを集計対象とする。（地方単独公費のみのレセプトは集計対象外）※12　厚労省「調剤医療費の動向～平成28年度版～」制度別後発医薬品割合（数量ベース）（都道府県別）より、協会一般と全保険者のジェネリック医薬品使用割合の差分。※13　影響度は偏差値50からの差分が、県全体のジェネリック医薬品使用割合に与える影響を示す。例えば、影響度が+0.6ならば、当該指標が県全体のジェネリック割合を0.6ポイント引き上げていることを意味する。　　　　影響度は、該当指標の全体平均からの差分に数量構成割合の比率を乗じて算出している。数量構成割合は地域によって異なるため、全体の影響度とその内訳の合計は必ずしも一致しない。

病院 診療所病院 診療所

入院外来

院内処方ジェネリック医薬品使用割合院内処方率（※6）

一般名処方率（※7）

都道府県コード

都道府県名※1

ジェネリック医薬品使用割合（全体）（※2、3、4、5）

院内処方 院外処方

【薬局の視点】 【患者の視点】

加入者ジェネリック拒否割合（※10）

公費対象者ジェネリック医薬品使用割合（※11）

全保険者とのジェネリック医薬品使用割合の乖離（※12）

調剤ジェネリック医薬品使用割合（院外処方再掲）

一般名処方限定調剤ジェネリック医薬品使用割合（※8）

院外処方率（※9）